11/25
08:29 am
ctxr
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "hold" rating re-affirmed by analysts at D. Boral Capital.
High
Report
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "hold" rating re-affirmed by analysts at D. Boral Capital.
11/25
08:12 am
ctxr
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval [Yahoo! Finance]
High
Report
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval [Yahoo! Finance]
11/25
08:03 am
ctxr
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
Medium
Report
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
11/22
09:14 am
ctxr
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split [Yahoo! Finance]
Medium
Report
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split [Yahoo! Finance]
11/22
09:00 am
ctxr
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
High
Report
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
11/18
04:05 pm
ctxr
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
High
Report
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
11/15
01:30 pm
ctxr
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
High
Report
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
11/12
08:33 am
ctxr
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/11
08:45 am
ctxr
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Low
Report
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors